Cancer continues to be a major global health challenge. Recent breakthroughs in molecular biology and multi-omics technologies have revolutionized the understanding of disease pathology and treatment modalities. Molecular Targets in Cancer Therapy is a cutting-edge resource that explores the rapidly evolving landscape of targeted cancer treatments, offering critical insights into the molecular mechanisms driving tumors growth and progression.

This comprehensive book brings together contributions from leading cancer researchers who examine a wide range of molecular targets- that are involved in hall marks of cancer, i.e. cell signalling pathways, angiogenesis, cell death pathways, epithelial mesenchymal transitions, telomerase, immune signalling, metabolic attributes etc. Each chapter delves into the biological rationale, current therapeutic strategies, and clinical implications of targeting these molecules, offering readers both foundational knowledge and the latest advances in the field.

Autorentext

Dr. Anand Shankar Ramteke

Anand Shankar Ramteke did his doctorate in Life Sciences from Jawaharlal Nehru University, New Delhi, India with a specialization in the area of radiation and cancer biology. He has been working in the area of exosome biology, tumor microenvironment and drug resistance in head and neck, breast and prostate cancers. His research interest also includes developing a nano-bio system for targeted drug delivery for cancer therapy. Presently he is working as a Professor at Tezpur University, Tezpur, Assam, India. and has published high impact papers in the field. He was also a visiting Professor/Faculty at the University of Oklahoma Health Sciences, Oklahoma, USA and the University of Colorado, Denver, USA.

Dr. Suresh Kumar Ramakrishnan

Suresh Kumar Ramakrishnan did his doctorate in Life Sciences from Jawaharlal Nehru University, New Delhi India. He worked in the field of non-canonical function of telomerase in cancer cells and unraveled telomerase RNA function in controlling cellular physiology. His interest also lies in epigenetic modifications, drug resistance, and chemoprevention in cancers. He was a visiting scientist at The Wistar Institute, Philadelphia, USA and worked in the field of non-coding RNAs in cancer. Presently he is working as a Scientist F at ICMR-National Institute of Cancer Prevention and Research, Noida, Uttar Pradesh, India.

Dr. Rajesh Agarwal

Rajesh Agarwal graduated from Lucknow University, Lucknow, India and worked at several positions in India and CWRU, Cleveland, USA. Presently he is working as a Professor in the Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado, Anschutz Medical Campus (UC-AMC), Aurora, CO, USA. He is a pioneer in cancer pharmacology and chemoprevention and has published more than 400 research papers in high impact journals. He is a fellow of the American Association for the Advancement of Science, and a recipient of several national and international awards.